利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.013 秒)

    NOVEL EP4 AGONIST
    1.
    发明申请
    NOVEL EP4 AGONIST 有权

    公开(公告)号：US20110098481A1

    公开(公告)日：2011-04-28

    申请号：US12917935

    申请日：2010-11-02

    申请人： Takahiko MURATA ,  Masahiro AMAKAWA ,  Shin TERADAIRA ,  Yasushi MATSUMURA ,  Katsuhiko KONISHI

    发明人： Takahiko MURATA ,  Masahiro AMAKAWA ,  Shin TERADAIRA ,  Yasushi MATSUMURA ,  Katsuhiko KONISHI

    IPC分类号： C07D405/06

    CPC分类号： C07D405/06 ,  A61K31/41

    摘要： Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.

    摘要翻译： 本发明提供由式（1）表示的化合物：其中，R 1和R 2各自独立地为氢原子或碳数为1-3的直链烷基，R 3为氢原子，具有碳数的烷基 1-4，烷氧基烷基，芳基，卤原子或卤代烷基，或其药学上可接受的盐，其与已知的PGI 2类似物不同，具有选择性EP4激动剂作用，和含有该化合物的药物，其中 可用于预防和/或治疗免疫疾病，消化道疾病，心血管疾病，心脏病，呼吸系统疾病，神经系统疾病，眼科疾病，肾病，肝病，骨病，皮肤疾病等。

    Cell migration inhibitor
    2.
    发明申请
    Cell migration inhibitor 审中-公开
    细胞迁移抑制剂

    公开(公告)号：US20050014675A1

    公开(公告)日：2005-01-20

    申请号：US10497653

    申请日：2002-12-05

    申请人： Masahiro Amakawa ,  Takahiko Murata

    发明人： Masahiro Amakawa ,  Takahiko Murata

    IPC分类号： A61K31/00 ,  A61K38/25 ,  A61P9/00 ,  A61P9/10 ,  A61P13/12 ,  A61P43/00 ,  A61K38/22

    CPC分类号： A61K31/00 ,  A61K38/25

    摘要： An agent for prevention or treatment of vascular disease and renal dysfunction that are accompanied by the migration of vascular smooth muscle cells and mesangial cells comprises as an active ingredient a growth-hormone secretion promoting substance receptor agonist that have a strong inhibitory action on the migration of vascular smooth muscle cells and mesangial cells. Using such an agent for prevention or treatment, one can suppress arteriosclerosis, recurrence of intimal thickening after angioplasty, and even glomerulosclerosis.

    摘要翻译： 伴随着血管平滑肌细胞和肾小球膜细胞迁移的血管疾病和肾功能障碍的预防或治疗药物包括作为活性成分的生长激素分泌促进物质受体激动剂，其具有对迁移的强烈抑制作用 血管平滑肌细胞和肾小球系膜细胞。 使用这种药剂进行预防或治疗，可以抑制动脉硬化，血管成形术后的内膜增厚复发，甚至肾小球硬化。

    EP4 agonist
    3.
    发明授权
    EP4 agonist 有权
    EP4激动剂

    公开(公告)号：US08394844B2

    公开(公告)日：2013-03-12

    申请号：US12917935

    申请日：2010-11-02

    申请人： Takahiko Murata ,  Masahiro Amakawa ,  Shin Teradaira ,  Yasushi Matsumura ,  Katsuhiko Konishi

    发明人： Takahiko Murata ,  Masahiro Amakawa ,  Shin Teradaira ,  Yasushi Matsumura ,  Katsuhiko Konishi

    IPC分类号： A61K31/34 ,  A61K31/495 ,  C07D257/04 ,  C07D307/00 ,  C07D307/93

    CPC分类号： C07D405/06 ,  A61K31/41

    摘要： Provided is a compound represented by the formula (1): wherein R1 and R2 are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R3 is a hydrogen atom, an alkyl group having a carbon number of 1 -4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI2 analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.

    摘要翻译： 本发明提供由式（1）表示的化合物：其中，R 1和R 2各自独立地为氢原子或碳数为1-3的直链烷基，R 3为氢原子，具有碳数的烷基 1-4烷氧基烷基，芳基，卤原子或卤代烷基，或其药学上可接受的盐，与已知的PGI 2类似物不同，具有选择性EP4激动剂作用，和含有该化合物的药物，其中 可用于预防和/或治疗免疫疾病，消化道疾病，心血管疾病，心脏病，呼吸系统疾病，神经系统疾病，眼科疾病，肾病，肝病，骨病，皮肤疾病等。